Cargando…

Posaconazole exposure in critically ill ICU patients: a need for action

PURPOSE: Posaconazole is an antifungal drug currently being used for prophylaxis and treatment of invasive fungal infections such as aspergillosis. To date, therapeutic drug monitoring (TDM) of posaconazole is recommended with the use of oral suspension, but the potential need of TDM with the use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	König, Christina, Göpfert, Melanie, Kluge, Stefan, Wichmann, Dominic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665255/ https://www.ncbi.nlm.nih.gov/pubmed/37498488 http://dx.doi.org/10.1007/s15010-023-02078-9

Ejemplares similares

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance
por: König, Christina, et al.
Publicado: (2021)

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
por: Sime, Fekade B., et al.
Publicado: (2019)

Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649
por: König, Christina, et al.
Publicado: (2021)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

ICU survival and need of renal replacement therapy with respect to AKI duration in critically ill patients
por: Truche, A. S., et al.
Publicado: (2018)

Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report
por: Verfaillie, Saartje, et al.
Publicado: (2022)

Chronic Critical Illness in Patients with COVID-19: Characteristics and Outcome of Prolonged Intensive Care Therapy
por: Roedl, Kevin, et al.
Publicado: (2022)

Standards of referrals and admissions of critically ill patients to the ICU
por: Ng, A
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in Germany: a single-center retrospective 10-year analysis
por: Schroeder, Maria, et al.
Publicado: (2020)

Interhospital transport of critically ill patient with dedicated ICU ventilator
por: Vacchi, R, et al.
Publicado: (2009)

Use of anabolic steroid therapy in critically ill ICU patients
por: Pikul, J, et al.
Publicado: (2003)

Scoring Systems in Assessing Survival of Critically Ill ICU Patients
por: Sekulic, Ana D., et al.
Publicado: (2015)

Innate and adaptive immune dysregulation in critically ill ICU patients
por: Duggal, Niharika Arora, et al.
Publicado: (2018)

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial
por: Vanderbeke, Lore, et al.
Publicado: (2021)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

Efficacy of introducing a checklist to reduce central venous line associated bloodstream infections in the ICU caring for adult patients
por: Wichmann, Dominic, et al.
Publicado: (2018)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

Gynecomastia and hypertension in a patient treated with posaconazole
por: Thompson, George R., et al.
Publicado: (2020)

Outcome of critically ill patients with haematological malignancy admitted to the ICU as an emergency
por: Lofaro, T, et al.
Publicado: (2013)

Daily interruption of central venous catheters in critically ill ICU patients
por: Myrianthefs, P, et al.
Publicado: (2004)

Outcome and prognostic factors in critically ill immunocompromised patients admitted to the ICU
por: Schellongowski, P, et al.
Publicado: (2004)

Hypocaloric nutrition and outcome in critically ill patients with prolonged ICU stay
por: Iff, S, et al.
Publicado: (2008)

Admission of critically ill patients with cancer to the ICU: many uncertainties remain
por: Koutsoukou, Antonia
Publicado: (2017)

Incidence of thrombotic complications in critically ill ICU patients with COVID-19
por: Klok, F.A., et al.
Publicado: (2020)

ICU-acquired bloodstream infections in critically ill patients with COVID-19()
por: Kokkoris, S., et al.
Publicado: (2021)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
por: Tikiso, Tjokosela, et al.
Publicado: (2023)

SARS-CoV-2 Blood RNA Load Predicts Outcome in Critically Ill COVID-19 Patients
por: Heinrich, Fabian, et al.
Publicado: (2021)

Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19—A Retrospective Study
por: Roedl, Kevin, et al.
Publicado: (2021)

Repurposing Lansoprazole and Posaconazole to treat leishmaniasis: Integration of in vitro testing, pharmacological corroboration, and mechanisms of action
por: Gupta, Yash, et al.
Publicado: (2022)

Role of posaconazole in the treatment of oropharyngeal candidiasis
por: Ianas, Voichita, et al.
Publicado: (2010)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole
por: Boughton, Charlotte, et al.
Publicado: (2018)

Posaconazole: An Update of Its Clinical Use
por: Leung, Simon, et al.
Publicado: (2015)

Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016)

Posaconazole-Induced Apparent Mineralocorticoid Excess
por: Pandit, Amar, et al.
Publicado: (2020)

Posaconazole treatment of refractory coccidioidomycosis in dogs
por: Shubitz, Lisa F., et al.
Publicado: (2021)

Posaconazole: Lack of efficacy: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sf7vaacl31h3d2jnsgdsk9c6oq